Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$166M |
| 2 |
Roivant Sciences
ROIV
|
+$137M |
| 3 |
Immunovant
IMVT
|
+$130M |
| 4 |
BridgeBio Pharma
BBIO
|
+$96.5M |
| 5 |
Baidu
BIDU
|
+$94.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$498M |
| 2 |
Amazon
AMZN
|
+$398M |
| 3 |
Charles Schwab
SCHW
|
+$372M |
| 4 |
Aon
AON
|
+$365M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$286M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 54.84% |
| 2 | Miscellaneous | 21.83% |
| 3 | Communication Services | 8.41% |
| 4 | Technology | 5.7% |
| 5 | Financials | 3.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
126
Grifois
GRFS
$5.07B
| – | – |
-28,000
| Closed | -$225K | – |
|
127
Garrett Motion
GTX
$4.1B
| – | – |
-275,000
| Closed | -$5M | – |
|
128
Hyatt Hotels
H
$16.7B
| – | – |
-36,000
| Closed | -$5.18M | – |
|
129
Hims & Hers Health
HIMS
$6.8B
| – | – |
-10,000
| Closed | -$208K | – |
|
130
HealthEquity
HQY
$8.35B
| – | – |
-2,800
| Closed | -$234K | – |
|
131
Healthcare Realty
HR
$6.14B
| – | – |
-12,000
| Closed | -$204K | – |
|
132
Inter&Co
INTR
$2.98B
| – | – |
-614,500
| Closed | -$4.89M | – |
|
133
Ionis Pharmaceuticals
IONS
$7.3B
| – | – |
-4,800
| Closed | -$360K | – |
|
134
Iovance Biotherapeutics
IOVA
$6.41B
| – | – |
-26,000
| Closed | -$91.3K | – |
|
135
Ironwood Pharmaceuticals
IRWD
$590M
| – | – |
-13,000
| Closed | -$45.6K | – |
|
136
Krystal Biotech
KRYS
$9.48B
| – | – |
-1,000
| Closed | -$258K | – |
|
137
Littelfuse
LFUS
$8.9B
| – | – |
-15,000
| Closed | -$5.09M | – |
|
138
LivaNova
LIVN
$4.48B
| – | – |
-6,000
| Closed | -$381K | – |
|
139
Mastercard
MA
$555B
| – | – |
-435,071
| Closed | -$217M | – |
|
140
McKesson
MCK
$118B
| – | – |
-234,300
| Closed | -$203M | – |
|
141
Madrigal Pharmaceuticals
MDGL
$10.5B
| – | – |
-3,319
| Closed | -$1.74M | – |
|
142
Mirum Pharmaceuticals
MIRM
$5.4B
| – | – |
-3,000
| Closed | -$277K | – |
|
143
Merit Medical Systems
MMSI
$5.61B
| – | – |
-3,000
| Closed | -$207K | – |
|
144
Molina Healthcare
MOH
$11.3B
| – | – |
-35,000
| Closed | -$4.67M | – |
|
145
MasTec
MTZ
$13.8B
| – | – |
-17,000
| Closed | -$5.47M | – |
|
146
NeoGenomics
NEO
$2.11B
| – | – |
-19,000
| Closed | -$141K | – |
|
147
Nektar Therapeutics
NKTR
$1.32B
| – | – |
-4,000
| Closed | -$288K | – |
|
148
ServiceNow
NOW
$162B
| – | – |
-41,000
| Closed | -$4.29M | – |
|
149
Nuvation Bio
NUVB
$1.65B
| – | – |
-29,000
| Closed | -$124K | – |
|
150
DELISTED
Nuvalent
NUVL
| – | – |
-3,000
| Closed | -$307K | – |
|
Similar funds
Thomas Steyer's Q2 2026 Portfolio in Review
As of Q2 2026, Thomas Steyer held 194 positions worth $21.7B, up 14% from $19.1B the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Thomas Steyer withdrew a net $3.46B in Q2 2026, closing 105 positions and reducing 23 holdings. Its most notable exit was Charles Schwab, an estimated $372M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 47% a quarter earlier, followed by Miscellaneous and Communication Services.
Against the trend, Thomas Steyer opened a new position in Parabilis Medicines Inc worth $64.8M.
- Thomas Steyer's largest Q2 2026 buy was Parabilis Medicines Inc: 2,368,200 shares worth $64.8M.
- Thomas Steyer added most to Boston Scientific in Q2 2026, an estimated $166M increase.
- Thomas Steyer's biggest Q2 2026 reduction was Microsoft, cutting an estimated $498M.
- Thomas Steyer fully exited Charles Schwab in Q2 2026, selling an estimated $372M.
- Thomas Steyer's ten largest holdings make up 62% of its $21.7B portfolio in Q2 2026.
- Thomas Steyer opened 19 new positions and closed 105 in Q2 2026.
- Thomas Steyer's portfolio value rose 14% quarter-over-quarter to $21.7B.
Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.